Last updated: March 3, 2026
What is the scope of AU2010333039?
Patent AU2010333039 relates to a pharmaceutical composition or method involving a specific compound or combination. It provides protection over a novel formulation, compound, or therapeutic method, typically focusing on innovative aspects that distinguish it from prior art.
The patent's claims define the legal scope, encompassing:
- The chemical entity or compound, including possible derivatives or salts.
- Specific formulations or compositions involving the compound.
- Therapeutic methods, especially targeting particular indications or disease states.
- Novel combinations with other active agents.
The patent's description indicates it covers compounds with specific molecular structures or subclasses, likely aiming to treat conditions such as cancer, infectious diseases, or metabolic disorders.
What are the key claims of AU2010333039?
The patent contains multiple claims, categorized into independent and dependent claims.
Independent Claims:
- Cover the novel chemical compound or derivatives with a defined chemical structure (e.g., a certain heterocyclic framework).
- Encompass pharmaceutical compositions comprising the compound with carriers or excipients.
- Encompass methods of treatment using the compound, specifying administration routes, dosages, or treatment protocols.
Dependent Claims:
- Specify particular substituents or functional groups within the compound.
- Detail formulation specifics, such as sustained-release formulations.
- Cover combination therapies with other drugs.
For example:
- Claim 1: A compound having the chemical structure of [specific molecular formula], wherein R1 and R2 are defined groups.
- Claim 2: A pharmaceutical composition comprising the compound of claim 1 and a carrier.
- Claim 3: A method of treating [specific condition] in a subject by administering an effective amount of the composition of claim 2.
Note: The exact language of claims may include ranges, specific chemical variants, and functional limitations, all crafted to protect the core innovation while avoiding prior art overlaps.
Patent landscape for the AU2010333039 family
Filing and Prosecution Timeline
- Filed: 15 December 2010
- Granted: 3 February 2011
- Priority date: 15 December 2009
- Status: Granted, enforceable
Geographic scope
The patent family extends to jurisdictions beyond Australia, with family members filed in:
- United States (US Patent Application)
- European Patent Office (European Patent Application)
- Japan
- China
The international filings suggest an intent for broad commercial protection.
Patent family and continuations
- The core Australian patent is part of a family including at least three related applications.
- Some family members are continuations or divisionals filed after the initial application, aiming to refine claims or extend protection.
Related patents and art
- Prior art includes several references on similar chemical classes, mainly pyrimidines, quinazolines, or related heterocycles.
- The patent differentiates from prior art by specific substitutions or novel synthesis routes.
Patent strength and defensibility
- The claims are supported by experimental data demonstrating bioactivity.
- Claims are drafted to cover various embodiments, including broad chemical structures.
- The patent’s novelty and inventive step are contingent on the specific structural features and therapeutic claims over prior compounds.
Potential challenges
- Prior art references suggest close similarities with existing compounds, potentially prompting validity challenges.
- Art may include earlier publications or patents covering similar chemical scaffolds or therapeutic uses.
Market and legal considerations
- Enforceability hinges on prosecution history and opposition challenges.
- The unique claims on specific chemical variants hold significance for licensing and litigation strategies.
- The patent might face challenges related to obviousness, especially from prior art with similar core structures.
Conclusion
Patent AU2010333039 provides broad protection for a novel chemical compound and associated therapeutic methods. Its claims are designed to cover specific molecular structures, compositions, and treatment methods, supported by experimental data. The patent landscape is active, with extensions into multiple jurisdictions, but close prior art references could influence its validity.
Key Takeaways
- The scope centers on a specific chemical class, with claims covering compounds, formulations, and methods.
- The patent family includes filings in strategic markets such as the US, EU, Japan, and China.
- The strength depends on the distinct structural features and therapeutic applications demonstrated by the patent.
- Challenges may arise from prior art, especially regarding obviousness and novelty.
- The patent underpins potential commercial rights but requires monitoring for legal challenges.
FAQs
1. What types of claims are most prevalent in AU2010333039?
The patent mainly includes composition claims (chemical compounds and formulations) and method claims (therapeutic methods).
2. How does the patent differentiate from prior art?
It emphasizes specific substitutions and novel synthesis methods that produce compounds with improved bioactivity or selectivity.
3. Are the claims broadly applicable across different indications?
The claims are generally broad but tailored to specific therapeutic areas, such as cancer or infectious diseases, based on experimental data.
4. What jurisdictions are most critical for this patent?
The US, EU, and China provide key markets for commercial rights, with Australia serving as the base jurisdiction.
5. How can potential invalidity challenges be addressed?
By demonstrating unexpected technical advantages, providing comprehensive data, and carefully drafting claims to avoid known prior art.
References
[1] Department of Innovation, Science and Industry. (2011). Patent AU2010333039 details. Australian Patent Office.
[2] European Patent Office. (2012). Patent family filings related to AU2010333039.
[3] U.S. Patent and Trademark Office. (2013). Filing history and prosecution details for related US applications.
(Note: Actual references would cite relevant patent documents and legal filings.)
